Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jan Brandt

Showing results (31-40 of 45) with videos related to

Pageof 5
Sort By:
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 29, 2020
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA StudyPiotr Wiland, Sławomir Jeka, Eva Dokoupilová, et al.
The Lancet. Rheumatology|January 22, 2024
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trialMichaela Koehm, Tanja Rossmanith, Ann C Foldenauer, et al.
Therapeutic Advances in Musculoskeletal Disease|August 25, 2022
Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional studyJulia Schally, Henning Christian Brandt, Jan Brandt-Jürgens, et al.
Annals of the Rheumatic Diseases|January 16, 2024
Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trialFabian Proft, Murat Torgutalp, Burkhard Muche, et al.
RMD Open|November 2, 2022
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional studyFabian Proft, Julia Schally, Henning Christian Brandt, et al.
Therapeutic Advances in Musculoskeletal Disease|April 4, 2022
Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional studyFabian Proft, Julia Schally, Henning Christian Brandt, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safetyFrank Heldmann, Xenofon Baraliakos, Uta Kiltz, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Advances in Therapy|May 8, 2020
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA StudyUta Kiltz, Petros P Sfikakis, Karl Gaffney, et al.
RMD Open|April 17, 2023
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseasesRebecca Hasseli, Jutta G Richter, Bimba Franziska Hoyer, et al.
Pageof 5

Showing results (31-40 of 45) with videos related to

Sort By:
Pageof 5
Biodrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy|October 29, 2020
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA StudyPiotr Wiland, Sławomir Jeka, Eva Dokoupilová, et al.
The Lancet. Rheumatology|January 22, 2024
Methotrexate plus ustekinumab versus ustekinumab monotherapy in patients with active psoriatic arthritis (MUST): a randomised, multicentre, placebo-controlled, phase 3b, non-inferiority trialMichaela Koehm, Tanja Rossmanith, Ann C Foldenauer, et al.
Therapeutic Advances in Musculoskeletal Disease|August 25, 2022
Validation of the Simplified Disease Activity Index (SDAI) with a quick quantitative C-reactive protein assay (SDAI-Q) in patients with rheumatoid arthritis: a prospective multicenter cross-sectional studyJulia Schally, Henning Christian Brandt, Jan Brandt-Jürgens, et al.
Annals of the Rheumatic Diseases|January 16, 2024
Comparison of the effect of treatment with NSAIDs added to anti-TNF therapy versus anti-TNF therapy alone on the progression of structural damage in the spine over 2 years in patients with radiographic axial spondyloarthritis from the randomised-controlled CONSUL trialFabian Proft, Murat Torgutalp, Burkhard Muche, et al.
RMD Open|November 2, 2022
Evaluation of the Disease Activity index for PSoriatic Arthritis (DAPSA) with a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis: a prospective multicentre cross-sectional studyFabian Proft, Julia Schally, Henning Christian Brandt, et al.
Therapeutic Advances in Musculoskeletal Disease|April 4, 2022
Validation of the ASDAS with a quick quantitative CRP assay (ASDAS-Q) in patients with axial SpA: a prospective multicentre cross-sectional studyFabian Proft, Julia Schally, Henning Christian Brandt, et al.
Clinical and Experimental Rheumatology|April 7, 2016
Clinical experience with the European Ankylosing Spondylitis Infliximab Cohort (EASIC): long-term extension over 7 years with focus on clinical efficacy and safetyFrank Heldmann, Xenofon Baraliakos, Uta Kiltz, et al.
Annals of the Rheumatic Diseases|June 2, 2025
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 studyPeter C Taylor, Philip J Mease, Kurt de Vlam, et al.
Advances in Therapy|May 8, 2020
Secukinumab Use in Patients with Moderate to Severe Psoriasis, Psoriatic Arthritis and Ankylosing Spondylitis in Real-World Setting in Europe: Baseline Data from SERENA StudyUta Kiltz, Petros P Sfikakis, Karl Gaffney, et al.
RMD Open|April 17, 2023
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseasesRebecca Hasseli, Jutta G Richter, Bimba Franziska Hoyer, et al.
Pageof 5